This study investigated the sparing effect on oclacitinib of several types of ceramide products in dogs with atopic dermatitis (AD). A total of 16 dogs with AD were enrolled. All dogs were treated with systemic oclacitinib (0.4–0.6 mg/kg, orally once daily) for at least three months. The dogs were randomly divided into two groups and treated with either a combination of oral and topical spray of ceramide products or topical spot-on ceramide products for 84 days. Oclacitinib was continuously administered in all cases at the regular dose (0.4–0.6 mg / kg, once daily) for 42 days. From Day (D)42 to D63, oclacitinib was tapered to half the dose (0.2–0.3 mg / kg, once daily), then administered every other day through to D84. Clinical assessments included the Canine Atopic Dermatitis Extent and Severity Index 4th iteration (CADESI-04) and the pruritus Visual Analog Scale (PVAS) every three weeks. In both groups, there were no significant differences in the mean CADESI-04 and PVAS scores before and after tapering of oral oclacitinib (P>0.05). In addition, there were no intergroup differences in each score at each endpoint (P>0.05). These results suggest that a combination of oral and topical ceramide products or a spot-on ceramide product may be useful for sparing oclacitinib therapy in dogs with AD.

A post-marketing surveillance study was conducted to assess the safety and efficacy of LOMEWON^®, 0.3% lomefloxacin otic solution, for bacterial otitis externa in dogs. In this study, we performed a safety study to investigate the incidence of adverse drug reactions to LOMEWON^®. We also performed an efficacy study to investigate its efficacy, and to compare its bacteriological efficacy with that of the clinical trial results. Among 613 cases, 3 adverse drug reactions were reported: vomiting, ear abrasion, and external auditory canal lesion. The incidence rate of adverse drug reactions was 0.49%. The efficacy rate of 103 cases in the efficacy study was 66.0%. Furthermore, the disappearance rates of S. intermedius, S. canis, and P. aeruginoca were 77.1%, 79.0%, and 92.3%, respectively, showing that LOMEWON^® had high efficacy in eradicating these bacterial species. These results indicate that LOMEWON^® is a useful drug with a low incidence rate of adverse drug reactions.

A 7-years-old, mix breed, male dog was referred to our hospital with intractable dermatitis. About one year earlier, this dog had been referred to a veterinarian who had been treating it for dermatitis around the prepuce. Initially, we diagnosed with iatrogenic Cushing disease with steroid dermatopathy and modified the treatment. After tapering oral prednisolone and discontinuing the topical steroid, the dog recovered in 5 months. After a further 1 month, a nodular lesion was observed around the preputial orifice. A biopsy was performed and, a histopathological diagnosis of epitheliotropic T-cell lymphoma was made. Complete remission has been sustained for approximately 10 months following resection.